RVMD — Revolution Medicines Balance Sheet
0.000.00%
- $15.26bn
- $13.12bn
- 40
- 18
- 84
- 45
Annual balance sheet for Revolution Medicines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 441 | 577 | 645 | 1,853 | 2,289 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6.39 | 5.93 | 4.67 | 1.25 | 0 |
| Prepaid Expenses | |||||
| Total Current Assets | 454 | 590 | 660 | 1,879 | 2,328 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 36.3 | 71.2 | 73.7 | 100 | 142 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 567 | 738 | 812 | 2,062 | 2,558 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 47.2 | 60.4 | 62 | 144 | 164 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 92.7 | 135 | 127 | 236 | 293 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Unrealized Gain / Loss | |||||
| Total Equity | 475 | 603 | 685 | 1,826 | 2,265 |
| Total Liabilities & Shareholders' Equity | 567 | 738 | 812 | 2,062 | 2,558 |
| Total Common Shares Outstanding |